Camomile tea for aches and ills

Drinking camomile tea can fight a cold and banish menstrual cramps, UK researchers believe.
Five cups a day for a fortnight is enough to boost urine levels of substances that can ease muscle spasms and fight inflammation.
The team from London's Imperial College tested the urine of 14 healthy camomile tea drinkers.
Their research will appear in the Journal of Agricultural and Food Chemistry.
A host of ills
For years, people have used camomile as an anti-inflammatory, a mild sedative and as an anti-ulcer remedy.
It has also been reported to have anti-oxidant activity and the essential oil extracted from the chamomile flowers has been shown to possess antimicrobial activity.
Dr Elaine Holmes and colleagues set out to investigate what happens in the body when a person drinks camomile tea.
In the study, the tea was made with the flowers of German camomile (Matricaria recutita), also known as manzanilla.
The researchers tested the volunteers' urine daily, both before and after they had consumed the camomile tea.
There may be something there, but what we need are controlled clinical trials.
Professor Ron Eccles, from the Common Cold Centre in Cardiff
Drinking tea caused levels of both glycine, which can ease muscle spasms, and the anti-inflammatory hippurate in the urine to go up.
After the volunteers stopped drinking the tea at the end of the two weeks, levels of glycine and hippurate stayed elevated for up to a further two weeks, which suggests the effects may be long-lasting.
Professor Ron Eccles, from the Common Cold Centre in Cardiff, said: "This interesting but it really is a very long way off evidence that camomile tea will have effects on colds and menstrual pain.
"There may be something there, but what we need are controlled clinical trials."
He said the best way to avoid colds was to stay healthy by exercising and eating a balanced diet.
"You can try remedies like camomile tea and echinacea, and if they work for you that's fine.
"Also, you can take symptomatic treatments - pain killers and hot tasty drinks," he said.
Maureen Robertson, from the Scottish School of Herbal Medicine, said camomile worked by removing heat from the body.
"It's a very safe herb to use. It's good for inflammation, particularly of the gastrointestinal tract."
She said the high essential oil content of camomile also made it a good antiseptic.
She said camomile infused oil could be massaged over the pubic area as a remedy for menstrual spasms.
But she said pregnant women should be cautious about using camomile because of its action on the womb

What You Can Do to Stay Healthy [ As a Precautionay Measures ]

Stay informed. This website will be updated regularly as information becomes available.
Influenza is thought to spread mainly person-to-person through coughing or sneezing of infected people.
Take everyday actions to stay healthy.
Cover your nose and mouth with a tissue when you cough or sneeze. Throw the tissue in the trash after you use it.
Wash your hands often with soap and water, especially after you cough or sneeze. Alcohol-based hands cleaners are also effective.
Avoid touching your eyes, nose or mouth. Germs spread that way.
Stay home if you get sick. we recommends that you stay home from work or school and limit contact with others to keep from infecting them.
Follow public health advice regarding school closures, avoiding crowds and other social distancing measures.
Find healthy ways to deal with stress and anxiety.

Vaccines for the new influenza A(H1N1)

Is an effective vaccine already available against the new influenza A(H1N1) virus?
No, but work is already under way to develop such a vaccine. Influenza vaccines generally contain a dead or weakened form of a circulating virus. The vaccine prepares the body’s immune system to defend against a true infection. For the vaccine to protect as well as possible, the virus in it should match the circulating “wild-type” virus relatively closely. Since this H1N1 virus is new, there is no vaccine currently available made with this particular virus. Making a completely new influenza vaccine can take five to six months.

What implications does the declaration of a pandemic have on influenza vaccine production?
Declaration by WHO of phase 6 of pandemic alert does not by itself automatically translate into a request for vaccine manufacturers to immediately stop production of seasonal influenza vaccine and to start production of a pandemic vaccine. Since seasonal influenza can also cause severe disease, WHO will take several important considerations such as the epidemiology and the severity of the disease when deciding when to formally make recommendations on this matter. In the meantime, WHO will continue to interact very closely with regulatory and other agencies and influenza vaccine manufacturers.

How important will influenza A(H1N1) vaccines be for reducing pandemic disease?
Vaccines are one of the most valuable ways to protect people during influenza epidemics and pandemics. Other measures include anti-viral drugs, social distancing and personal hygiene.

Will currently available seasonal vaccine confer protection against influenza A(H1N1)?
The best scientific evidence available today is incomplete but suggests that seasonal vaccines will confer little or no protection against influenza A(H1N1).

What is WHO doing to facilitate production of influenza A(H1N1) vaccines?
As soon as the first human cases of new influenza A(H1N1) infection became known to WHO, the WHO Collaborating Center in Atlanta (The Centers for Disease Control and Prevention (CDC) in the United States of America) took immediate action and began the work to develop candidate vaccine viruses. WHO also initiated consultations with vaccine manufacturers worldwide to facilitate the availability of all necessary material to start production of influenza A(H1N1) vaccine. In parallel, WHO is working with national regulatory authorities to ensure that the new influenza A(H1N1) vaccine will meet all safety criteria and be made available as soon as possible.

Why is WHO not asking vaccine manufacturers to switch production from seasonal vaccine to a influenza A(H1N1) vaccine yet?
WHO has not recommended stopping production of seasonal influenza vaccine because this seasonal influenza causes 3 million to 5 million cases of severe illness each year, and kills from 250 000 to 500 000 people. Continued immunization against seasonal influenza is therefore important. Moreover, stopping seasonal vaccine production immediately would not allow a pandemic vaccine to be made quicker. At this time, WHO is liaising closely with vaccine manufacturers so large-scale vaccine production can start as soon as indicated.

Is it possible that manufacturers produce both seasonal and pandemic vaccines at the same time?
There are several potential options which must be considered based on all available evidence.

What is the process for developing a pandemic vaccine? Has a vaccine strain been identified, and if so by whom?
A vaccine for the Influenza A(H1N1) virus will be produced using licensed influenza vaccine processes in which the vaccine viruses are grown either in eggs or cells. Candidate vaccine strains have been identified and prepared by the WHO Collaborating Center in Atlanta (The Centers for Disease Control and Prevention (CDC) in the United States of America)1. These strains have now been received by the other WHO Collaborating Centers which have also started preparation of vaccine candidate viruses. Once developed, these strains will be distributed to all interested manufacturers on request. Availability is anticipated by mid-May.

How quickly will influenza A(H1N1) vaccines be available?
The first doses of Influenza A(H1N1) vaccine could be available in five to six months from identification of the pandemic strain. The regulatory approval will be conducted in parallel with the manufacturing process. Regulatory authorities have put into place expedited processes that do not compromise on the quality and safety of the vaccine. Delays in production could result from poor growth of the virus strain used to make the vaccine.

How would manufacturers be selected?
There are currently more than a dozen vaccine manufacturers with licenses to produce influenza vaccines. Upon request, the vaccine strain will be available to each of them, as well as to other qualified vaccine manufacturers who are preparing to make influenza vaccine but do not yet have a licensed influenza vaccine.

What is the global manufacturing capacity for a potential influenza A(H1N1) pandemic vaccine? Is this the same as the global manufacturing capacity for H5N1?
The projections made for the production capacity of an vaccine for H5N1 cannot be automatically assumed to be the capacity to make an H1N1 vaccine. H5N1 and H1N1 viruses are different and the amount of antigen needed to make an effective H1N1 vaccines may be different than for H5N1. Therefore it is not possible to make a precise estimate. However, given these considerations, a conservative estimate of global capacity is at least 1 to 2 billion doses per year.

How is production capacity for influenza vaccines distributed geographically?
More that 90% of the global capacity today is located in Europe and in North America. However, during the past five years, other regions have begun to acquire the technology to produce influenza vaccines. Six manufacturers in developing countries have done so with technical and financial support from WHO.

What will be the storage requirements for influenza A(H1N1) vaccine?
The vaccine should be stored under refrigerated conditions at between 2°C and 8°C.

It has been impossible so far to develop vaccines for major killers such as HIV and malaria. How sure are we that there will not be scientific or other hurdles in developing an effective influenza A(H1N1) vaccine?
Typically, development of influenza vaccines has not posed a problem. Influenza vaccines have been used in humans for many years and are known to be immunogenic and effective. Each year seasonal influenza vaccines with varying composition are produced for the northern and southern hemisphere influenza seasons. Vaccine manufacturers will employ a number of different technologies to develop their vaccines. They will take advantage, notably, of novel approaches that were developed over the past years for H5N1 avian influenza vaccines. One key unknown is yield of vaccine virus production, since some strains grow better than others and the behavior of the new influenza A(H1N1) strain in manufacturers’ systems is not yet known. New recombinant technologies are under development, but have not yet been approved for use.

Will influenza A(H1N1) vaccines be effective in all population groups?
There are not data on this but there also is no reason to expect that they would not, given current information.

Will the influenza A(H1N1) vaccine be safe?
Licensed vaccines are held to a very high standard of safety. All possible precautions will be taken to ensure safety of new influenza A(H1N1) vaccines.

How can a repeat of the 1976 swine flu vaccine complications (Guillain-Barré syndrome) experienced in the United States of America be avoided?
Guillain-Barré syndrome is an acute disorder of the nervous system. It is observed following a variety of infections, including influenza. Studies suggest that regular seasonal influenza vaccines could be associated with an increased risk of Guillain-Barré syndrome on the order of one to two cases per million vaccinated persons. During the 1976 influenza vaccination campaign, this risk increased to around 10 cases per million vaccinated persons which led to the withdrawal of the vaccine.

Pandemic vaccines will be manufactured according to established standards. However, they are new products so there is an inherent risk that they will cause slightly differently reactions in humans. Close monitoring and investigation of all serious adverse events following administration of vaccine is essential. The systems for monitoring safety are an integral part of the strategies for the implementation of the new pandemic influenza vaccines. Quality control for the production of influenza vaccines has improved substantially since the 1970s.

Will it be possible to deliver new influenza A(H1N1) vaccine simultaneously with other vaccines?
Inactivated influenza vaccine can be given at the same time as other injectable vaccines, but the vaccines should be administered at different injection sites.

If the virus causes a mild pandemic in the warmer months and changes into something much more severe in, say, 6 months, will vaccines being developed now be effective?
It is too early to be able to predict changes in the influenza A(H1N1) virus as it continues to circulate in humans or how similar a mutated virus might be to the current virus. Careful surveillance for changes in the influenza A(H1N1) virus is ongoing. This close and constant monitoring will support a quick response should important changes in the virus be detected.

Will there be enough influenza A(H1N1) vaccine for everyone?
The estimated time to make enough vaccine to vaccinate the world's population against pandemic influenza will not be known until vaccine manufacturers will have been able to determine how much active ingredient (antigen) is needed to make one dose of effective influenza A(H1N1) vaccine.

In the past two years, influenza vaccine production capacity has increased sharply due to expansion of production facilities as well as advances in research, including the discovery and use of adjuvants. Adjuvants are substances added to a vaccine to make it more effective, thus conserving the active ingredient (antigen).

What is WHO's perspective on fairness and equity for vaccine availability?
The WHO Director-General has called for international solidarity in the response to the current situation. WHO regards the goal of ensuring fair and equitable access by all countries to response measures to be among the highest priorities. WHO is working very closely with partners including the vaccine manufacturing industry on this.

Who is likely to receive priority for vaccination with a future pandemic vaccine?
This decision is made by national authorities. As guidance, WHO will be tracking the evolution of the pandemic in real-time and making its findings public. As information becomes available, it may be possible to better define high-risk groups and to target vaccination for those groups, thus ensuring that limited supplies are used to greatest effect.

Will WHO be conducting mass influenza A(H1N1) vaccination campaigns?
No. National authorities will implement vaccination campaigns according to their national pandemic preparedness plans. WHO is exploring whether the vaccine can be packaged, for example, in multi-dose vials, to facilitate the rapid and efficient vaccination of large numbers of people.

Developing countries are very experienced in administering population-wide vaccination campaigns during public health emergencies caused by infectious diseases, including diseases like epidemic meningitis and yellow fever, as well as for polio eradication and measles control programmes.

How feasible will it be to immunize large numbers of people in developing countries against a pandemic virus?
Developing countries have considerable strategic and practical experience in delivering vaccines in mass campaigns. The main issue is not feasibility, but how to ensure timely access to adequate quantities of vaccine.

What is the estimated global number of doses of seasonal vaccine used annually?
The current annual demand is for less than 500 million doses per year.

Will seasonal influenza vaccine continue to be available?
At this time there is no recommendation to stop production of seasonal influenza vaccine.

1National Institute for Biological Standards and Control (UK), Food and Drug Administration/Center for Biologics Evaluation and Research (USA), New York Medical College (USA), Victorian Infectious Diseases Research Laboratory (Australia)

swine influenza A (H1N1) virus - انفلونزا الخنازير

إنفلونزا الخنازير- آخر التطورات/3
27 نيسان/أبريل 2009 -- تشهد الأوضاع الراهنة فيما يخص فاشية إنفلونزا الخنازير من النمط A/H1N1 تطوراً سريعاً. فقد أبلغت حكومة الولايات المتحدة الأمريكية، في 27 نيسان/أبريل 2009، عن وقوع 40 حالة مؤكّدة من حالات العدوى البشرية بفيروس إنفلونزا الخنازير من النمط A/H1N1 لم تؤد أيّة حالة منها إلى الوفاة. وأبلغت المكسيك عن حدوث 26 حالة مؤكّدة من حالات العدوى البشرية الناجمة عن الفيروس نفسه أدّت سبع حالات منها إلى الوفاة. كما أبلغت كندا عن وقوع ست حالات لم تؤد أيّة حالة منها إلى الوفاة، بينما أبلغت إسبانيا عن حدوث حالة واحدة لم تؤد إلى الوفاة
ولا توصي المنظمة بفرض أيّة قيود على حركة السفر العادية أو غلق الحدود. وينبغي للمرضى، من باب الحيطة، إرجاء رحلاتهم الدولية، كما ينبغي لمن تظهر عليهم أعراض عقب رحلة دولية التماس الرعاية الطبية وذلك طبقاً للإرشادات ذات الصلة الصادرة عن السلطات الوطنية.

والجدير بالذكر أيضاً أنّه لا توجد أيّة مخاطر لاكتساب العدوى بهذا الفيروس جرّاء استهلاك لحوم الخنازير ومشتقاتها التي تم طهيها بطريقة جيدة. ويُنصح الناس بغسل أيديهم بالماء والصابون على نحو كاف وبانتظام والتماس الرعاية الطبية إذا ما ظهرت عليهم أعراض تشبه أعراض الإنفلونزا.
27 April 2009 -- The current situation regarding the outbreak of swine influenza A(H1N1) is evolving rapidly. As of 27 April 2009, the United States Government has reported 40 laboratory confirmed human cases of swine influenza A(H1N1), with no deaths. Mexico has reported 26 confirmed human cases of infection with the same virus, including seven deaths. Canada has reported six cases, with no deaths, while Spain has reported one case, with no deaths.

Further information on the situation will be available on the WHO website on a regular basis.

WHO advises no restriction of regular travel or closure of borders. It is considered prudent for people who are ill to delay international travel and for people developing symptoms following international travel to seek medical attention, in line with guidance from national authorities.

There is also no risk of infection from this virus from consumption of well-cooked pork and pork products. Individuals are advised to wash hands thoroughly with soap and water on a regular basis and should seek medical attention if they develop any symptoms of influenza-like illness.

وزارة الصحة المصرية: الفسيخ قد يؤدي الي الشلل التام او الوفاة

حذرت وزارة الصحة المواطنين من تناول الفسيخ نظرا لما يمثله من خطر داهم على الصحة قد تصل الى الشلل التام او الوفاة وطالبتهم بسرعة التوجه إلى المستشفى أو مركز علاج السموم عند ظهور أية أعراض مرضية خلال 24 ساعة من تناوله.

وقال الدكتور عبدالرحمن شاهين المستشار الاعلامى والمتحدث الرسمى لوزارة الصحة المصرية إنه بمناسبة قرب حلول عيد شم النسيم أصدرت وزارة الصحة تعليماتها إلى جميع مديريات الشئون الصحية بالمحافظات لاتخاذ الترتيبات والاستعدادات اللازمة خلال الاحتفال بشم النسيم.

وأضاف أن أساس مشكلة التسمم الناتج عن أكل الفسيخ يرجع إلى طريقة التحضير التى قد تكون غير آمنة من الناحية الصحية لقلة وجود الملح بالفسيخ وعدم تركه وقتا كافيا لمدة لا تقل عن 30 يوما ، منبها إلى أن البعض قد يستخدم الأسماك الطافية على سطح الماء والتى قد ماتت وتعرضت لاشعة الشمس وبدأت تنتفخ وتتحلل وأصبحت لها رائحة كريهة ثم يضيفون عليها قليلا من الملح وبيعها على أنها فسيخ بعد ثلاثة أو أربعة أيام .

ولفت إلى أن السموم الموجودة بالفسيخ لا يبطل مفعولها وتأثيرها على الانسان الا اذا تعرض الفسيخ لدرجة حرارة مائة درجة مئوية لمدة عشر دقائق مثل القلى فى الزيت .

من جانبه أشار الدكتور نصر السيد مساعد وزير الصحة للشئون الوقائية والرعاية الصحية الاساسية وتنظيم الاسرة أن عام 2007 حدثت فيه 49 إصابة توفى منها 9 وفى عام 2008 حدثت 26 اصابة توفى منها 7 حالات . مشيرا الى ان العام الحالى لم يشهد اية حالات تسمم بالفسيخ حتى الان .

وقال إن انخفاض حالات الاصابة تدريجيا خلال الأعوام السابقة جاء نتيجة لتضافر جهود الاعلام مع الوزارة . مشيرا إلى أن مصر استهلكت أمصالا مضادة للتسمم الناتج عن أكل الفسيخ قيمتها 2 مليون جنيه العام الماضى .

وأضاف أنه نتيجة المرور المكثف على محلات بيع الفسيخ والاسماك المملحة ورفع وعى المواطنين بخطورة تناوله لم تحدث أية حالات تسمم منذ شم النسيم من العام الماضى.

مشيرا إلى ان التسمم الناتج عن تناول الفسيخ المسمم قد حدث بصورة وبائية فى مصر عام 1991 وأصاب 90 حالة توفى منها 18 وتم انقاذ الباقين باعطائهم المصل المضاد.

من ناحية أخرى ، قال الدكتور عمرو قنديل رئيس الادارة المركزية للشئون الوقائية بوزارة الصحة إن الاعراض الاولى للتسمم تظهر بعد 8 الى 12 ساعة من تناول الفسيخ ، وهى عبارة عن زغللة فى العين وازدواجية فى الرؤية وجفاف بالحلق وصعوبة فى الكلام والبلع وضعف بالعضلات تبدأ بالاكتاف والاطراف العليا وتنتقل إلى باقى الجسم بالاضافة الى ضيق بالتنفس واذا لم يتم وضع المريض على جهاز التنفس الصناعى تكون حياته معرضة للخطر.

وأوضح أنه يتم إعطاء المصاب المصل المضاد للسم وهو الدواء الوحيد الذى يعطى فى مثل هذه الحالات والمصرح به ويتم حقنه بالوريد ليتعادل مع جزئيات السم التى تؤثر على الجهاز الهضمى للانسان وهو عبارة عن زجاجة 250 مم وقد يحتاج المصاب لزجاجة أخرى ، مشيرا الى ان عمر المصل المضاد فى الدورة الدموية يتراوح من 5 إلى 8 أيام.

وقال إنه لزيادة فاعلية المصل ولمنع مضاعفات المرض وسرعة العلاج يجب أن يأخذ فى الأيام الأولى من الإصابة مشيرا إلى أن تكلفة المصل الواحد لعلاج المريض تصل الى 60 ألف جنيه.

FDA Alerts Consumers to Recall of Certain Pistachios

FDA Alerts Consumers to Recall of Certain Pistachios
FDA and California Inspectors Identify Salmonella
The FDA and the California Department of Public Health (CDPH) are investigating Salmonella contamination in pistachio products sold by Setton Pistachio of Terra Bella Inc, Calif. The company has stopped all distribution of processed pistachios and will issue a voluntary recall involving approximately 1 million pounds of its products. Because the pistachios were used as ingredients in a variety of foods, it is likely this recall will impact many products. In addition, the investigation at the company is ongoing and may lead to additional pistachio product recalls.

The contamination involves multiple strains of Salmonella. Salmonella can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Thus far, several illnesses have been reported by consumers that may be associated with the pistachios. It is not yet known whether any of the Salmonella strains found in the pistachio products are linked to an outbreak. The FDA is conducting genetic testing of the samples to pursue all links.

FDA is working closely with the pistachio industry and recommends that consumers avoid eating pistachio products until further information is available about the scope of affected products.

FDA will provide a searchable database of affected products at www.fda.gov and will continue to update the public.

FDA first learned of the problem on March 24, when it was informed by Kraft Foods that its Back To Nature Trail Mix was found to be contaminated with Salmonella. Kraft had identified the source of the contamination to be pistachios from Setton and conducted a recall.
& from yahoo health
FDA says to avoid pistachios amid salmonella scare
FRESNO, Calif. – Federal food safety officials warned Monday that consumers should stop eating all foods containing pistachios while they figure out the source of a possible salmonella contamination.

Still reeling from the national salmonella outbreak in peanuts, the Food and Drug Administration said central California-based Setton Pistachio of Terra Bella Inc., the nation's second-largest pistachio processor, was voluntarily recalling a portion of the roasted nuts it has been shipping since last fall. A Setton spokeswoman said that amounts to more than 2 million pounds of nuts.

"Our advice to consumers is that they avoid eating pistachio products, and that they hold onto those products," said Dr. David Acheson, assistant commissioner for food safety. "The number of products that are going to be recalled over the coming days will grow, simply because these pistachio nuts have then been repackaged into consumer-level containers."

Two people called the FDA complaining of gastrointestinal illness that could be associated with the nuts, but the link hasn't been confirmed, Acheson said. Still, the plant decided to shut down late last week, officials said.

The recalled nuts represent a small fraction of the 55 million pounds of pistachios that the company's plant processed last year and an even smaller portion of the 278 million pounds produced in the state in the 2008 season, according to the Fresno-based Administrative Committee for Pistachios.

California alone is the second-largest producer of pistachios in the world.

According to the company's Web site, Setton Pistachio is in the corporate family of Commack, N.Y.-based Setton International Foods Inc. The company sells nuts, dried fruit, edible seeds, chocolate and yogurt-coated candies.

The FDA learned about the problem last Tuesday, when Kraft Foods Inc. notified the agency that it had detected salmonella in roasted pistachios through routine product testing. Kraft and the Georgia Nut Co. recalled their Back to Nature Nantucket Blend trail mix the next day.

The FDA contacted Setton Pistachio and California health officials shortly afterward, in what Acheson called a "proactive move."

By Friday, grocery operator Kroger Co. recalled one of its lines of bagged pistachios because of possible salmonella contamination, saying the California plant also supplied its nuts. Those nuts were sold in 31 states.

Fabia D'Arienzo, a spokeswoman for Tulare County-based Setton Pistachio, said the company was only recalling certain bulk roasted in-shell and roasted shelled pistachios that were shipped on or after September 1.

Because Setton Pistachio shipped tote bags of nuts weighing up to 2,000 pounds to 36 wholesalers across the country, it will take weeks to figure out how many products could be affected, said Jeff Farrar, chief of the Food and Drug Branch of the California Department of Public Health.

"It will be safe to assume based on the volume that this will be an ingredient in a lot of different products, and that may possibly include things like ice cream and cake mixes," Farrar said. "The firm is already turning around trucks in transit to bring those back to the facility."

Salmonella, the most common cause of food-borne illness, is a bacteria that causes diarrhea, fever and cramping. Most people recover, but the infection can be life-threatening for children, the elderly and people with weakened immune systems.

For nuts, roasting is supposed to kill the bacteria. But problems can occur if the roasting is not done correctly or if roasted nuts are re-contaminated. That can happen if mice, rats or birds get into the facility.

Last winter, a national salmonella outbreak was blamed on a Georgia company under federal investigation for flouting safety procedures and knowingly shipping contaminated peanuts.

The outbreak is still ongoing. More than 690 people in 46 states have gotten sick. Nearly 3,900 products made with peanut ingredients from Peanut Corp of America have been recalled.

California public health authorities have taken hundreds of samples at Setton's processing facility, but lab results have not yet determined whether salmonella was found at the plant, Farrar said. The food companies' own tests of the contaminated products isolated four different types of salmonella, but none were the same strain as the one found in the peanuts, Acheson said.

http://www.settonfarms.com

أربع مشروبات مضاده للسرطان -Things which prevent Cancer

1- عصير الطماطم
عصير الطماطم تلعب مادة الليكوبين التي تكسب الطماطم لونها الاحمر دورا كبيرا في الوقايه من السرطان واكدت د راسه حديثه اجريت في جامعة جون هوبكنز الاميركيه ان إمكانيه الإصابه بسرطان البنكرياس تزدادخمسة أضعاف لدى الأشخاص الذين ينخفض معدل مادة الليكوبين في دمائهم

2- الشــاي
الشاي كما يوكد الأطباء في مجمع الصحه الميركي على مكافحة بعض انواع السرطان مثل سرطان الجهاز الهضمي والبروستاتا والجلد فالشاي الاسود يحتوي على الكاتشنز وهي ماده مضاده للسرطان لكن الافضل منه هو الشاي الاخضر الذي يحتوي على نسبه أكبر بكثير من هذه الماده

3- الحليب
الحليب أكدت دراسة حديثه أجرتها مؤسسه روزويل بارك الأميركيه وشملت 1300 شخص في بافلو أن الاشخاص الذين يشربون الحليب القليل الدسم يكونون أقل عرضه للإصابه بسرطان المعدة و المثانة والصدر والرحم من الأشخاص الذين لا يشربون الحليب

4- عصير الجزر
عصير الجزر الجزر غني جدا بالبيتاكاروتين المضاد للأكسده والذي يساهم في كبح تطور الأورام وتبين من الدراسات و التجارب التي أجراها صندوق الأبحاث السرطانيه الملكي ان تناول البيتاكاروتين يخفف من إمكانية الإصابه بسرطان الرئه النفـــس